Menu
Recruiting NCT06745557

Phase III Study with an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents

Phase III Interventional Burns

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: denovoSkin(TM), STSG.
Who it may be relevant to
Registry conditions: Burns. Basic parameters: from 12 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Netherlands
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Multicentre, Intra-patient Randomised Controlled Phase III Study to Confirm the Efficacy and Safety of DenovoSkin™, a Bilayer Engineered Collagen-based Skin Graft Composed of Autologous Fibroblasts and Keratinocytes, for the Treatment of Patients with Deep Partial and Full-thickness Burns

Overview

This multicentre phase III clinical trial will target adults and adolescents of 12 years and older with severe burns to confirm the efficacy and functionality of denovoSkin™ in achieving wound closure and reducing scarring in patients with deep partial and full-thickness burns as compared to split-thickness skin.

Interventions

  • Biological denovoSkin(TM)
    Transplantation of autologous dermo-epidermal skin substitute denovoSkin(TM) to the experimental area
  • Other STSG
    Transplantation of autologous split-thickness skin to the control area

Primary outcome measures

  • A composite endpoint whereby success is defined by meeting both of the following criteria: - Wound closure - Scar quality (POSAS v2.0) [Time frame: 6 months post grafting]
Secondary outcome measures (7)
  • Ratio of covered surface area to biopsy site/donor site surface area at 4 weeks post-grafting [Time frame: 4 weeks]
  • Assessment of scar contracture [Time frame: 6 months post grafting]
  • Epithelialisation percentage at 3 months and 6 months post-grafting [Time frame: 3 months and 6 months post-grafting]
  • Graft take at 14 and 21 days post-grafting [Time frame: 14 and 21 days post-grafting]
  • Assessment of the donor sites [Time frame: 4 and 10 weeks, and 3, 6, 12, and 24 months post-grafting]
  • Assessment of the grafted burn wounds areas [Time frame: 4 and 10 weeks and 3, 6, 12, and 24 months post-grafting]
  • Assessment of scar contracture [Time frame: 12 and 24 months post-grafting]

Eligibility criteria

Inclusion criteria

  • Patients with deep partial or full-thickness thermal burns of ≥20% total body surface area (TBSA) for which excision and standard of care (SOC) (STSG) are clinically indicated
  • Patients of either sex aged ≥12 years
  • Signed informed consent from the patient and/or legally authorised representative

Exclusion criteria

  • Burn wound areas solely located on the head and neck (i.e., test and control areas must NOT be located on head/neck)
  • Patients eligible to have all areas autografted in a single surgery or significantly earlier than the end of the manufacturing period of denovoSkin™, for whom the application of denovoSkin™ would delay the standard of care therapies
  • Patients with serologic evidence of active hepatitis B virus (HBV) infection (i.e., positive for Hepatitis B surface antigen \[HbsAg\] or immunoglobulin M total hepatitis B core antibody \[anti-HBc\]), active hepatitis C infection (hepatitis C virus \[HCV\] antibody positive), positive human immunodeficiency virus (HIV) serology, or positive Treponema pallidum serology assessed as per local standard of care; cured hepatitis C (defined as documented treatment and negative viral load) is not an exclusion
  • Patients with known underlying or concomitant medical conditions that, in the opinion of the Investigator, has the potential to significantly delay wound healing, e.g., glycated haemoglobin (HbA1c) ≥53 mmol/mol and/or systemic skin and connective tissue diseases
  • Patients with pre-existing coagulation disorders as defined by international normalised ratio (INR) outside its normal value, a prothrombin time (PT) greater than the upper limit of normal, and fibrinogen less than the lower limit of normal prior to the current hospital admission
  • Patients with a history of clinically significant hypersensitivity to amphotericin B, gentamicin, penicillin, streptomycin, or bovine collagen and it's derivatives (e.g. gelatine)
  • Previous treatment with denovoSkin™
  • Participation in any clinical interventional study within 60 days prior to the first IMP administration in case of monoclonal antibodies and <30 days for all other IMPs
  • Patients unwilling or unable to comply with procedures required in this clinical study protocol
  • Pregnant or lactating women
  • Women of child-bearing potential not using highly effective method(s) of birth control (i.e., with low failure rate <1% per year) throughout the study and/or unwilling to be tested for pregnancy. A negative serum beta-human chorionic gonadotropin (β-hCG) test is required on the day of grafting
  • Patient is the Investigator, one of his/her family members, employees, and other dependent persons

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Netherlands · 1 center
  • Rode Kruis Ziekenhuis — Beverwijk

Identifiers

NCT: NCT06745557 · dS-BA-PIII

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗